Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2012-03-08

Original market date: See footnote 1

2012-03-08

Product name:

YERVOY

Description:

FOR I.V. INFUSION ONLY. 50MG/10ML AND 200MG/40 ML SINGLE USE VIALS.

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section .

DIN:

02379384

Product Monograph/Veterinary Labelling:

Date: 2021-04-26 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company: 

BRISTOL-MYERS SQUIBB CANADA
2344 Boul. Alfred-Nobel, Suite 300
Montréal (St-Laurent)
Quebec
Canada  H4S 0A4

Class: 

Human

Dosage form(s):

Liquid

Route(s) of administration:

Intravenous

Number of active ingredient(s):

1

Schedule(s):

Prescription,  Schedule D  

Biosimilar Biologic Drug:

No

American Hospital Formulary Service (AHFS): See footnote 3

10:00.00   ANTINEOPLASTIC AGENTS

Anatomical Therapeutic Chemical (ATC): See footnote 4

L01XC11  IPILIMUMAB

Active ingredient group (AIG) number:See footnote 5

0153088001

List of active ingredient(s)
Active ingredient(s) Strength
IPILIMUMAB 5 MG / ML

Application information

Related information

Contact us

Version 3.9.0
Date modified: